Hospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia

    Neurobiology of Aging, Vol. 99, pp. 99.e15-99.e22

  2. Present and future of parkinson’s disease in Spain: Parkinson-2030 delphi project

    Brain Sciences, Vol. 11, Núm. 8

  3. Spanish expert consensus on the use of safinamide in Parkinson's disease

    Neurologia, Vol. 36, Núm. 9, pp. 666-672

2020

  1. Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease

    Neurobiology of Aging, Vol. 87, pp. 139.e1-139.e7

2019

  1. Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism

    Movement Disorders, Vol. 34, Núm. 10, pp. 1547-1561

  2. Reply to: “Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion”

    Movement Disorders

2012

  1. levodopa en el tratamiento de la enfermedad de parkinson: Mitos y realidades

    Revista de Neurologia, Vol. 55, Núm. 11, pp. 669-688

2009

  1. Neuroprotección en la enfermedad de parkinson: Análisis a través de la metodología de informadores clave

    Neurologia, Vol. 24, Núm. 2, pp. 113-124